Screener
Charles River Laboratories CRL Equity Method Investments
Equity Method Investments at other companies
Other financials
Where this comes from
Reported directly by Charles River Laboratories in its filing.
Tagged under the XBRL concept us-gaap:EquityMethodInvestments.
The source filing: Charles River Laboratories’s 10-Q, filed August 5, 2026.
- Filed
- Aug 5, 2026, 9:21 AM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001100682-26-000118
| Line item | June 27, 2026 | December 27, 2025 |
|---|---|---|
| Other current assets | 178,657 | 129,212 |
| Total current assets | 1,529,106 | 1,447,049 |
| Property, plant and equipment, net | 1,494,914 | 1,655,219 |
| Venture capital and strategic equity investments | 206,470 | 206,972 |
| Operating lease right-of-use assets, net | 330,247 | 361,415 |
| Goodwill | 3,076,851 | 2,764,253 |
| Intangible assets, net | 253,174 | 339,995 |
| Deferred tax assets | 53,827 | 67,334 |
Item 1. Financial Statements
FAQ
- What is Charles River Laboratories's equity method investments?
- Charles River Laboratories (CRL) reported equity method investments of $206.47M in Q2 2026.
- How has Charles River Laboratories's equity method investments changed year-over-year?
- Charles River Laboratories's equity method investments decreased by 4.4% year-over-year, from $216.07M to $206.47M.
- What is the long-term trend for Charles River Laboratories's equity method investments?
- Over 5 years (2020 to 2025), Charles River Laboratories's equity method investments has grown at a 53.0% compound annual growth rate (CAGR), from $24.7M to $206.97M.
- What does equity method investments mean?
- Investments in unconsolidated affiliates and joint ventures where the company has significant influence (typically 20-50% ownership), carried at proportional book value.
Ask your AI about Charles River Laboratories's equity method investments.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude